BARCELONA, Spain--(BUSINESS WIRE)--Surefire Medical, Inc. today announced at the Cardiovascular and Interventional Radiological Society of Europe Annual Scientific Congress the results of a multi-center registry in which the use of the Surefire Precision Infusion System to deliver therapy in the treatment of primary liver cancer (hepatocellular carcinoma or HCC) was associated with a 68 percent complete tumor response and 92 percent objective tumor response.
The multi-center registry evaluated the use of Surefire Precision during transarterial chemoembolization (TACE) in 32 patients with 41 lesions. Among the institutions included in the study were Mt. Sinai Hospital, Piedmont Hospital, University of Southern California Medical Center, Georgetown University via MedStar Georgetown University Hospital, and the University of California at San Diego Medical Center.
“TACE procedures utilizing the Surefire Infusion System was shown to effectively deliver therapy to the tumor,” said Aravind Arepally, MD, Chief Scientific Officer for Surefire Medical. “The objective response rate shown in this multi-center registry is considerably higher when compared to the average response rate we see in the literature.”
Surefire Medical is also conducting a 140-patient, randomized controlled, multi-center study comparing the outcomes of Surefire to standard end-hole catheter for drug-eluting beads transarterial chemoembolization (DEB-TACE) treatments in HCC. The study, titled “Surefire vs. Endhole for DEB-TACE: Quantifying Hepatic Artery Embolization to Improve Outcomes”, is currently enrolling patients and seeking new sites.
About Surefire Medical
Surefire Medical is inventing the future for cancer care with advanced treatment technology. We are pioneers, developing liver cancer infusion systems that overcome the limitations of traditional tools and delivery methods. Clinical discoveries combined with new, precise technology enable physicians to target tumors with superior accuracy, control and protection. Our Colorado-based team of physicians, engineers and researchers are united in a mission to progress cancer care and offer new hope to patients. Learn more: www.surefiremedical.com.
